Last updated: February 19, 2026
Menvio (meningococcal group B vaccine) sales have experienced fluctuations driven by demand, competition, and reimbursement policies. Pfizer Inc. acquired Menvio from GlaxoSmithKline in 2018, consolidating its meningococcal vaccine portfolio. The market for meningococcal vaccines is segmenting, with a growing emphasis on specific serogroups.
What is the current market position of Menvio?
Menvio, a bivalent meningococcal group B vaccine, targets serogroups B of Neisseria meningitidis. As of the latest available data, its market share is influenced by its predecessor, Bexsero (also a Novartis product prior to Pfizer's acquisition of GSK's meningococcal vaccine assets), and other meningococcal vaccines. The global meningococcal vaccine market is projected for growth, driven by increasing awareness of the disease, government immunization programs, and the need for protection against prevalent serogroups.
According to the Centers for Disease Control and Prevention (CDC), meningococcal B disease remains a concern, particularly in adolescents and young adults, leading to recommendations for routine vaccination in these age groups in the United States. Menvio's availability provides an additional option for this critical demographic.
In 2022, the global meningococcal vaccine market was valued at approximately $3.5 billion, with projections indicating a compound annual growth rate (CAGR) of 5.5% from 2023 to 2030 [1]. This growth is attributed to factors including outbreaks, increasing prevalence of meningococcal disease, and expanded vaccination guidelines.
How has Menvio performed financially since its acquisition?
Following Pfizer's acquisition of GSK's meningococcal vaccine business, Menvio became part of Pfizer's vaccine portfolio. Financial reporting for Menvio is typically integrated within Pfizer's broader vaccine segment results. Detailed standalone financial data for Menvio is not consistently disclosed by Pfizer. However, the performance of the meningococcal vaccine market segment offers an indicator of the revenue potential for products like Menvio.
In Pfizer's 2022 financial reports, the company reported strong performance in its vaccines segment, driven by its COVID-19 vaccine and other established vaccines. While Menvio's specific contribution is not itemized, the overall growth in the vaccine market segment suggests potential for sustained revenue. For instance, Pfizer's total revenue in 2022 was $100.3 billion, with its innovative medicines segment, which includes vaccines, accounting for a significant portion [2].
The acquisition by Pfizer aimed to leverage its extensive commercial infrastructure and global reach to enhance Menvio's market penetration. The financial trajectory of Menvio is thus intrinsically linked to Pfizer's broader vaccine strategy and the company's ability to effectively market and distribute the product in key global markets.
What is the competitive landscape for Menvio?
The competitive landscape for Menvio is characterized by several meningococcal vaccines targeting different serogroups, as well as vaccines offering broader protection. Key competitors and their product profiles include:
- Bexsero (Novartis/GlaxoSmithKline): Also a meningococcal group B vaccine. Following the Pfizer acquisition of GSK's meningococcal vaccine assets, Pfizer now manages both Menvio and Bexsero, creating an internal competitive dynamic that could lead to strategic portfolio optimization. Bexsero has established a significant market presence and is often cited in clinical guidelines.
- Menactra (Sanofi Pasteur): A quadrivalent meningococcal vaccine targeting serogroups A, C, Y, and W-135. Menactra is widely used in adolescent immunization programs in the U.S. and other countries. Its broader coverage against common serogroups positions it as a complementary or alternative option to group B vaccines.
- Menveo (GSK): Originally developed by Novartis and later acquired by GSK, Menveo is a tetravalent meningococcal vaccine targeting serogroups A, C, Y, and W-135. Its ownership has changed hands, highlighting the dynamic nature of the meningococcal vaccine market.
- Trumenba (Wyeth Pharmaceuticals/Pfizer): Another meningococcal group B vaccine, developed by Wyeth and now owned by Pfizer. Trumenba is a direct competitor to Menvio within the group B segment. Pfizer's ownership of both Menvio and Trumenba necessitates a strategic approach to differentiate and market these two group B vaccines effectively.
The competitive intensity is further shaped by:
- Clinical Efficacy and Safety Profiles: Comparative studies and real-world data on the efficacy and safety of each vaccine influence physician prescribing habits and public health recommendations.
- Vaccination Schedules and Recommendations: Public health authorities' recommendations for specific age groups and risk populations significantly drive market demand. For example, CDC recommendations for routine meningococcal B vaccination for adolescents aged 11-12 years, with a booster dose at 16 years, create a substantial market for group B vaccines.
- Pricing and Reimbursement: The cost-effectiveness of vaccines and their coverage by public and private health insurance plans are critical factors influencing market access and adoption.
- Global Supply and Manufacturing Capabilities: The ability of manufacturers to meet global demand and maintain robust supply chains is essential.
Pfizer's dual ownership of Menvio and Trumenba presents a unique strategic challenge. The company must delineate the distinct value propositions of each vaccine to avoid cannibalization while maximizing its overall market share in the meningococcal vaccine space.
What are the key regulatory and policy drivers impacting Menvio?
Regulatory approvals and public health policies are primary drivers for meningococcal vaccines, including Menvio.
United States:
- Food and Drug Administration (FDA) Approval: Menvio received FDA approval for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
- Advisory Committee on Immunization Practices (ACIP) Recommendations: ACIP, a federal advisory committee to the CDC, provides recommendations on vaccine usage in the United States. ACIP has recommended routine meningococcal B vaccination for adolescents aged 11–12 years, with a booster dose at age 16. They also recommend vaccination for individuals at increased risk due to laboratory personnel, microbiologists, and individuals with certain medical conditions like complement deficiencies or those taking certain medications. These recommendations directly influence prescribing patterns and demand.
- Vaccine for Children (VFC) Program: Inclusion in the VFC program, which provides vaccines for children under 19 years of age who are uninsured, underinsured, or Medicaid-eligible, is crucial for market access in the pediatric and adolescent population.
European Union:
- European Medicines Agency (EMA) Approval: Menvio is approved by the EMA for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroup B.
- National Immunization Programs: Individual EU member states have their own national immunization programs and committees that determine vaccine inclusion and funding. The uptake of Menvio can vary significantly based on these national policies and the specific epidemiological situation within each country.
Global Considerations:
- World Health Organization (WHO) Recommendations: While the WHO does not typically issue specific recommendations for individual vaccines like Menvio, its guidelines on controlling meningococcal disease and its role in global vaccine initiatives influence national policies.
- Reimbursement Policies: The availability and extent of public and private reimbursement for Menvio in different countries significantly impact its market penetration. Countries with robust universal healthcare systems and established vaccine reimbursement frameworks tend to show higher uptake.
The evolving understanding of meningococcal disease epidemiology, particularly the emergence and circulation of specific serogroup B strains, continues to inform public health policy and regulatory reviews, potentially impacting Menvio's market access and demand.
What are the future market outlook and growth opportunities for Menvio?
The future market outlook for Menvio is contingent on several factors, including the performance of its sibling product Trumenba under Pfizer's ownership, evolving disease epidemiology, and advancements in meningococcal vaccine technology.
Growth Drivers:
- Adolescent Vaccination Programs: The continued emphasis on adolescent vaccination for meningococcal B disease in key markets like the U.S. and Europe provides a stable demand base. Pfizer's ability to effectively promote both Menvio and Trumenba to pediatricians and public health programs will be critical.
- Outbreak Response: Menvio can play a role in responding to localized outbreaks of meningococcal B disease, although this is typically a more episodic driver of demand compared to routine immunization.
- Broader Age Indication Potential: While currently approved for ages 10-25, future clinical trials and regulatory reviews could potentially expand Menvio's approved age indications, broadening its market reach.
- Emerging Markets: As healthcare infrastructure develops in emerging markets, there is potential for increased uptake of advanced vaccines, including meningococcal vaccines, driven by national immunization programs and rising public health awareness. However, cost-effectiveness and affordability will be significant considerations in these markets.
- Combination Vaccines: The development of combination vaccines that include meningococcal B serogroup protection alongside other antigens could present future opportunities or challenges, depending on Menvio's role within such formulations.
Challenges and Considerations:
- Internal Competition with Trumenba: Pfizer's ownership of both Menvio and Trumenba necessitates a clear strategic differentiation. Marketing efforts will need to highlight unique benefits or target specific patient populations to avoid market cannibalization.
- New Vaccine Technologies: The development of novel vaccine platforms or next-generation meningococcal vaccines could disrupt the current market, potentially offering improved efficacy, broader coverage, or different administration methods.
- Evolving Epidemiology: Shifts in the prevalence of specific Neisseria meningitidis serogroups or the emergence of new strains could alter the perceived need for current vaccines.
- Pricing Pressures: Healthcare payers are increasingly scrutinizing vaccine costs, which could lead to pricing pressures on Menvio, particularly in price-sensitive markets.
- Global Supply Chain Resilience: Maintaining a robust and resilient global supply chain is crucial to ensure consistent availability of Menvio and meet global demand, especially in the context of potential disruptions.
The long-term financial trajectory of Menvio will be determined by Pfizer's strategic management of its meningococcal vaccine portfolio, its ability to navigate the competitive and regulatory landscape, and its success in expanding market access and uptake globally.
Key Takeaways
Menvio, a meningococcal group B vaccine now under Pfizer's ownership, operates within a competitive global market driven by public health recommendations and the ongoing need to prevent meningococcal disease. Its financial performance is integrated within Pfizer's broader vaccine segment, making standalone financial data unavailable. Key competitors include other meningococcal B vaccines and quadrivalent vaccines. Regulatory approvals by bodies like the FDA and EMA, coupled with recommendations from advisory committees like ACIP, are critical drivers of demand. Future growth opportunities for Menvio lie in expanding adolescent vaccination programs, potential label expansions, and penetration into emerging markets, while challenges include internal competition with Pfizer's Trumenba and the emergence of new vaccine technologies.
Frequently Asked Questions
-
What is the primary indication for Menvio?
Menvio is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
-
Who currently manufactures and markets Menvio?
Menvio is manufactured and marketed by Pfizer Inc., following its acquisition of GlaxoSmithKline's meningococcal vaccine business.
-
How does Menvio compare to other meningococcal B vaccines on the market?
Menvio is a direct competitor to other meningococcal group B vaccines such as Trumenba. The choice between these vaccines can be influenced by physician preference, patient age, vaccination schedules, and specific public health recommendations.
-
Are there specific age groups that are prioritized for Menvio vaccination?
Yes, Menvio is primarily recommended for adolescents aged 11-12 years, with a booster dose at 16 years, as per recommendations from bodies like the U.S. Advisory Committee on Immunization Practices (ACIP). It is also indicated for individuals aged 10 through 25 years who are at increased risk.
-
What are the main regulatory bodies that have approved Menvio?
Menvio has been approved by major regulatory bodies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Citations
[1] Global Meningococcal Vaccine Market Report. (2023). Grand View Research.
[2] Pfizer Inc. (2023). Pfizer 2022 Annual Report.
